Guggenheim maintains Universal Health Services at Buy, lowers price target to $201 from $209

Guggenheim kept Universal Health Services at Buy but reduced its price target to $201 from $209, a 3.8% cut. The new target suggests 16.7% upside from the Oct 28 close of $172.18.

Original reporting
Published Oct 29, 2026, 6:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 6:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Guggenheim maintains Universal Health Services at Buy, lowers price target to $201 from $209 — source image
Decision brief

The 30-second read

$UHSBearishLow
01

Why it matters

The downgrade may prompt short-term traders to trim positions, while long-term holders may view it as a buying opportunity at lower implied upside.

02

Market read

A modest analyst target reduction with limited immediate market impact.

03

What to watch

Potential upside from upcoming contract wins or cost reductions not reflected in the target.

Relevance 7/10Novelty 5/10Timing: today

Background

Guggenheim maintains a Buy rating but reduces its price target, indicating a slightly less optimistic outlook.

Company-level read

Ticker impact

$UHSBearishMedium confidence
Context

Guggenheim lowered its price target for Universal Health Services to $201 from $209.

Expected impact

potential slight downside as the market prices in the lower target

Evidence & confidence

Target cut of 3.8% is a fresh analyst action; investors may adjust expectations but the change is modest.

Market effects

Minimal impact on the healthcare services sector; only reflects one analyst's view.

No broader regional effect.

Limited to investors tracking UHS.

Counterpoint

The target cut may be overly cautious if recent earnings beat expectations.

Key entities

  • Universal Health Services

    U.S.-listed provider of behavioral health and acute care services.

  • Guggenheim

    Investment research firm issuing the rating and target.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$CNCMed

Health insurers, hospitals rally after sweeping midterm win for Democrats

Shares of Medicaid-focused health insurers (Centene, Elevance, Molina) and hospital operators (HCA, Tenet, Universal) rose after Democrats won the midterms, raising hopes for sector-friendly policies. Analysts expect delays in Trump's OBBBA, easing pressure on Medicaid and ACA insurers, and potential extensions of enhanced subsidies. Year-to-date gains vary among companies.

$UHSHighAI 8/10

Softer surgery volumes, hospital woes dampened UHS’ Q3 earnings

Universal Health Services (UHS) lowered its 2026 earnings expectations due to declining surgeries and struggles at some hospitals. Q3 net income fell 17% to $308M, while revenues rose 5% to $4.7B. Challenges include lower surgery volumes, delays in new hospital profitability, and rising uninsured patients. UHS expects to be at the lower end of its guidance range for 2024.

$UHSMed

Guggenheim cuts Universal Health Services stock price target to $201 on weak Q3

Guggenheim reduced its price target for Universal Health Services (UHS) to $201 from $209, citing weak Q3 2026 EBITDA and macro pressures. UHS stock is down 8.5% in a week. The company lowered its 2026 EBITDA guidance but sees potential upside from expansions. UHS reported Q3 EPS of $5.22 and revenue of $4.73B, slightly beating estimates. Raymond James kept a Market Perform rating, noting softer profit trends and a cautious 2027 outlook.

$UHSMedAI 8/10

Raymond James reiterates Universal Health Services stock rating

Raymond James maintained a Market Perform rating on Universal Health Services (UHS), citing Q3 results slightly below expectations and a cautious 2027 outlook. UHS stock is down 21% YTD, trading at $172.18. Analysts have lowered earnings estimates due to slower growth at new facilities. Despite near-term challenges, UHS is trading at a P/E ratio of 6.89, suggesting potential undervaluation.